The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells

References

• Greenfield L, Bjorn MJ, Horn G, Fong D, Buck GA, Collier RJ, Kaplan DA. 1983. Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta. Proc Natl Acad Sci U S A. 80(22):6853–6857. doi:10.1073/pnas.80.22.6853.
   PubMed Web of Science ®Google Scholar
• Kohno K, Uchida T. Highly frequent single amino acid substitution in mammalian elongation factor 2 (EF-2) results in expression of resistance to EF-2-ADP-ribosylating toxins. J Biol Chem. 1987;262(25):12298–12305.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Liu S, Leppla SH. 2010. Characterization of a Chinese hamster ovary cell mutant having a mutation in elongation factor-2. PLoS One. 5(2):e9078. doi:10.1371/journal.pone.0009078.
   PubMed Web of Science ®Google Scholar
• Shibata MA, Miwa Y, Miyashita M, Morimoto J, Abe H, Otsuki Y. 2005. Electrogene transfer of an Epstein-Barr virus-based plasmid replicon vector containing the diphtheria toxin A gene suppresses mammary carcinoma growth in SCID mice. Cancer Sci. 96(7):434–440. doi:10.1111/j.1349-7006.2005.00070.x.
   PubMed Web of Science ®Google Scholar
• Delhove J, Osenk I, Prichard I, Donnelley M. 2020. Public acceptability of gene therapy and gene editing for human use: a systematic review. Hum Gene Ther. 31(1–2):20–46. doi:10.1089/hum.2019.197.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Gao G. 2020. 2020: gene therapy enters its fourth decade. Hum Gene Ther. 31(1–2):2–3. doi:10.1089/hum.2019.29101.trf.
   PubMed Web of Science ®Google Scholar
• Xia Y, Wang L, Ma X, Li X. 2020. Investigation on the genomic characterization of uterine sarcoma for rAd-p53 combined with chemotherapy treatment. Hum Gene Ther. 31(15–16):881–890. doi:10.1089/hum.2019.305.
   PubMed Web of Science ®Google Scholar
• Zou H, Tuhin IJ, Monty MA, Luo S, Shao J, Yan Z, Yu L. 2020. Gene therapy for hepatocellular carcinoma using adenoviral vectors delivering a gene encoding IL-17A-neutralizing antibody fragments. Hum Gene Ther. 31(19–20):1074–1085. doi:10.1089/hum.2019.169.
   PubMed Web of Science ®Google Scholar
• Gahéry-Ségard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, Gautier E, Le Cesne A, Zitvogel L, Venet A, et al. 1997. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest. 100(9):2218–2226. doi:10.1172/jci119759.
   PubMed Web of Science ®Google Scholar
• Dinney CP, Fisher MB, Navai N, O’Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, et al. 2013. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 190(3):850–856. doi:10.1016/j.juro.2013.03.030.
   PubMed Web of Science ®Google Scholar
• Pearson S, Jia H, Kandachi K. 2004. China approves first gene therapy. Nat Biotechnol. 22(1):3–4. doi:10.1038/nbt0104-3.
   PubMed Web of Science ®Google Scholar
• Yamaizumi M, Mekada E, Uchida T, Okada Y. 1978. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 15(1):245–250. doi:10.1016/0092-8674(78)90099-5.
   PubMed Web of Science ®Google Scholar
• Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. 2004. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther. 11(11):740–747. doi:10.1038/sj.cgt.7700752.
   PubMed Web of Science ®Google Scholar
• Huang R, Zhao Z, Ma X, Li S, Gong R, Kuang A. 2011. Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter. Cancer Gene Ther. 18(2):144–152. doi:10.1038/cgt.2010.66.
   PubMed Web of Science ®Google Scholar
• Garg H, Salcedo R, Trinchieri G, Blumenthal R. 2010. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther. 17(3):155–163. doi:10.1038/cgt.2009.63.
   PubMed Web of Science ®Google Scholar
• Kageyama T, Ohishi M, Miyamoto S, Mizushima H, Iwamoto R, Mekada E. 2007. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J Biochem. 142(1):95–104. doi:10.1093/jb/mvm116.
   PubMed Web of Science ®Google Scholar
• Uchida T, Pappenheimer AM Jr., Greany R. Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem. 1973;248(11):3838–3844.
   PubMed Web of Science ®Google Scholar
• Qiao J, Ghani K, Caruso M. 2008. Diphtheria toxin mutant CRM197 is an inhibitor of protein synthesis that induces cellular toxicity. Toxicon. 51(3):473–477. doi:10.1016/j.toxicon.2007.09.010.
   PubMed Web of Science ®Google Scholar
• Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002;62(9):2576–2582.
   PubMed Web of Science ®Google Scholar
• Dai LX, Yang J, Liu JM, Huang S, Wang BN, Li H, Zhao ZY, Cao K, Li MY, Li M-Y. 2019. Adenovirus-mediated CRM197 sensitizes human glioma cells to gemcitabine by the mitochondrial pathway. Cancer Biother Radiopharm. 34(3):171–180. doi:10.1089/cbr.2017.2363.
   PubMed Web of Science ®Google Scholar
• Dai L, Pan Q, Peng Y, Huang S, Liu J, Chen T, Wang X, Chen D, Wang J, Zhu Y, et al. 2018. p53 plays a key role in the apoptosis of human ovarian cancer cells induced by adenovirus-mediated CRM197. Hum Gene Ther. 29(8):916–926. doi:10.1089/hum.2017.186.
   PubMedGoogle Scholar
• Fogar P, Navaglia F, Basso D, Zambon CF, Moserle L, Indraccolo S, Stranges A, Greco E, Fadi E, Padoan A, et al. 2010. Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy. Cancer Gene Ther. 17(1):58–68. doi:10.1038/cgt.2009.48.
   PubMed Web of Science ®Google Scholar
• Hou H, Zhang C, Qi X, Zhou L, Liu D, Lv H, Li T, Sun D, Zhang X. 2020. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis. Cancer Biol Ther. 21(1):26–33. doi:10.1080/15384047.2019.1665392.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo S, Zhao R, Liu Y, Yang G. 2019. STAT3-activated long non-coding RNA lung cancer associated transcript 1 drives cell proliferation, migration, and invasion in hepatoblastoma through regulation of the miR-301b/STAT3 Axis. Hum Gene Ther. 30(6):702–713. doi:10.1089/hum.2018.146.
   PubMed Web of Science ®Google Scholar
• Xie Z, Gu Y, Lin X, Ouyang M, Qin Y, Zhang J, Liu J, Mai S, Zhou C. 2019. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report. Cancer Biol Ther. 20(9):1172–1175. doi:10.1080/15384047.2019.1617561.
   PubMed Web of Science ®Google Scholar
• Hu X, Gu Y, Zhao S, Hua S, Jiang Y. 2019. Elevated circulating CD4(+)CD25(-)Foxp3(+) regulatory T cells in patients with nonsmall cell lung cancer. Cancer Biother Radiopharm. 34(5):325–333. doi:10.1089/cbr.2018.2672.
   PubMed Web of Science ®Google Scholar
• Mittal S, Rajala MS. 2020. Heat shock proteins as biomarkers of lung cancer. Cancer Biol Ther. 21(6):477–485. doi:10.1080/15384047.2020.1736482.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhuang Q, Zhuang W. 2020. Mortal obligate RNA transcript inhibits cancer cell invasion and migration in lung adenocarcinoma by downregulating miRNA-223. Cancer Biother Radiopharm 35(5):345–350. doi:10.1089/cbr.2019.3244.
   PubMed Web of Science ®Google Scholar
• Li M, Zhou CZ, Yang JJ, Lu S, Zheng D, Hu J, Zeng H, Lu Y, Lu KH, Li SA, et al. 2019. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. Cancer Biol Ther. 20(8):1097–1104. doi:10.1080/15384047.2019.1595280.
   PubMed Web of Science ®Google Scholar
• Lu H, Han X, Ren J, Ren K, Li Z, Sun Z. 2020. Circular RNA HIPK3 induces cell proliferation and inhibits apoptosis in non-small cell lung cancer through sponging miR-149. Cancer Biol Ther. 21(2):113–121. doi:10.1080/15384047.2019.1669995.
   PubMed Web of Science ®Google Scholar
• Dong Z, Liu H, Zhao G. 2020. Long noncoding RNA SNHG6 promotes proliferation and inhibits apoptosis in non-small cell lung cancer cells by regulating miR-490-3p/RSF1 Axis. Cancer Biother Radiopharm. 35(5):351–361. doi:10.1089/cbr.2019.3120.
   PubMed Web of Science ®Google Scholar
• Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, et al. 2017. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 31(2):286–299. doi:10.1016/j.ccell.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, et al. 2011. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med. 17(11–12):1262–1274. doi:10.2119/molmed.2011.00176.
   PubMed Web of Science ®Google Scholar
• Cao K, Yang J, Lin C, Wang BN, Yang Y, Zhang J, Dai J, Li L, Nie CL, Yuan Z, et al. 2012. Noxa enhances the cytotoxic effect of gemcitabine in human ovarian cancer cells. Cancer Biother Radiopharm. 27(4):259–266. doi:10.1089/cbr.2011.1126.
   PubMed Web of Science ®Google Scholar